MarketBeat
31 Oct 2026, 06:14 UTC · 2h ago
What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call
Impact · against what's priced in
The guidance raise for WST provides positive momentum but fails to close the gap between current performance and the aggressive 17.9% revenue CAGR the market valuation requires. While GLP-1 growth remains strong, it continues to track with existing expectations, and the SmartDose divestiture creates a new growth drag for 2027.
- WST+0.30
Challenges what's priced in
- The price assumes
Sustained revenue growth acceleration well beyond current guidance toward the 17.9% rate the valuation requires
The company raised its 2026 organic revenue growth ceiling to 11.6%, which is a positive step but still significantly below the 17.9% CAGR the current price demands.
What WST's price assumes · Sep 10
